Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Type (Gene Silencing), Vector (Viral (Retroviral, AAV), Non-Viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (in-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

The report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene therapy market. A detailed analysis of the key industry players has been completed to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. The report details new approvals/launches, collaborations and acquisitions, and recent developments associated with the gene therapy market.

The global gene therapy market is projected to reach USD 36.55 billion by 2032 from USD 8.85 billion in 2024, at a CAGR of 19.4% during the forecast period of 2024 to 2032. The growth of the gene therapy market has been significantly driven by increasing R&D investment by key players for the development gene therapy drugs and growing approval of novel gene therapies. However, complex regulatory frameworks and ethical concerns regarding genetic modifications are restraining market growth.

The intravenous route segment accounted for the largest share by route of administration in 2023

Based on route of administration, the gene therapy market is segmented into intravenous route, subcutaneous route and other routes. The intravenous route segment accounted for the largest share of the gene therapy market in 2023. The larger share of this segment is mainly attributed to the number of gene therapy administered through intravenous route is due to factors such as the high effectiveness of intravenous administration and high penetration of intravenous gene therapy currently approved and marketed products among others.

The US has continued to dominate the gene therapy market during the forecast period of 2024-2032

The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from chronid disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US).

The report provides insights on the following:

• Analysis of key drivers (Growing demand for curative therapies for genetic disorders, rare diseases, and specific types of cancer, Increasing investments in gene therapy research, Growing technological advancements, and Robust clinical trial pipeline for gene therapy), restraints (High cost of gene therapy products, Complex regulatory frameworks and ethical concerns regarding genetic modifications, and Limited manufacturing scalability), opportunities (Expansion into rare diseases and unmet needs, Increasing focus on precision medicine, and Advancements in gene therapy delivery technologies), and Challenges (Complex manufacturing process, Short shelf life and supply chain challenges, and Lack of reimbursement).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the gene therapy market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the gene therapy market.

Key Attributes:

Key Topics Covered:

Premium Insights

• Gene Therapy Market Overview
• North America: Gene Therapy Market, by Therapy Type & Country (2024)
• Gene Therapy Market Share, by End-user, 2024 vs 2032
• Gene Therapy Market: Geographic Growth Opportunities

Market Dynamics

Drivers

• Growing Demand for Curative Therapies for Genetic Disorders, Rare Diseases, and Cancers
• Increasing Investments in Gene Therapy Research
• Technological Advancements
• Robust Clinical Trial Pipeline for Gene Therapy

Restraints

• High Cost of Gene Therapy Products
• Complex Regulatory Frameworks and Ethical Concerns Regarding Genetic Modifications
• Limited Manufacturing Scalability

Opportunities

• Expansion into Rare Diseases and Unmet Needs
• Increasing Focus on Precision Medicine
• Advancements in Gene Therapy Delivery Technologies

Challenges

• Complex Commercial Manufacturing and Scaling Process
• Short Shelf Life and Supply Chain Challenges
• Lack of Reimbursement

Company Profiles

Key Players

• Biogen Inc.
• Novartis
• Alnylam Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Jazz Pharmaceuticals PLC
• Ferring B.V.
• Pfizer Inc.
• Amgen, Inc.
• Johnson & Johnson Services, Inc.
• Daiichi Sankyo Company, Limited.
• Biomarin Pharmaceutical Inc.
• Kyowa Kirin Co. Ltd.
• Nippon Shinyaku Co. Ltd.
• PTC Therapeutics
• Uniqure

Other Players

• Juventas Cell Therapy Ltd.
• Crispr Therapeutics
• Bluebird Bio, Inc.
• Krystal Biotech, Inc.
• Shanghai Sunway Biotech Co. Ltd.
• JW (Cayman) Therapeutics Co. Ltd
• Iaso Biotechnology
• Carsgen Therapeutics Holdings Limited
• Adaptimmune
• Sibiono Genetech Co. Ltd.
• Ultragenyx Pharmaceutical Inc.

For more information about this report visit https://www.researchandmarkets.com/r/p6n4g1

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Gene Therapy Market

            CONTACT: ResearchAndMarkets.com 
Laura Wood,Senior Press Manager 
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470 
For U.S./ CAN Toll Free Call 1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900